Stone J - Search Results

1

Functional neuroimaging in schizophrenia: diagnosis and drug discovery.

McGuire P, Howes OD, Stone J, Fusar-Poli P. McGuire P, et al. Among authors: stone j. Trends Pharmacol Sci. 2008 Feb;29(2):91-8. doi: 10.1016/j.tips.2007.11.005. Epub 2008 Jan 9. Trends Pharmacol Sci. 2008. PMID: 18187211 Review.

2

Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo.

Bressan RA, Erlandsson K, Stone JM, Mulligan RS, Krystal JH, Ell PJ, Pilowsky LS. Bressan RA, et al. Among authors: stone jm. Biol Psychiatry. 2005 Jul 1;58(1):41-6. doi: 10.1016/j.biopsych.2005.03.016. Biol Psychiatry. 2005. PMID: 15992521

3

Antipsychotic drug action: targets for drug discovery with neurochemical imaging.

Stone JM, Pilowsky LS. Stone JM, et al. Expert Rev Neurother. 2006 Jan;6(1):57-64. doi: 10.1586/14737175.6.1.57. Expert Rev Neurother. 2006. PMID: 16466312 Review.

4

Novel targets for drugs in schizophrenia.

Stone JM, Pilowsky LS. Stone JM, et al. CNS Neurol Disord Drug Targets. 2007 Aug;6(4):265-72. doi: 10.2174/187152707781387323. CNS Neurol Disord Drug Targets. 2007. PMID: 17691983 Review.

5

Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature.

Stone JM, Davis JM, Leucht S, Pilowsky LS. Stone JM, et al. Schizophr Bull. 2009 Jul;35(4):789-97. doi: 10.1093/schbul/sbn009. Epub 2008 Feb 26. Schizophr Bull. 2009. PMID: 18303092 Free PMC article.

6

Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume.

Stone JM, Day F, Tsagaraki H, Valli I, McLean MA, Lythgoe DJ, O'Gorman RL, Barker GJ, McGuire PK; OASIS. Stone JM, et al. Biol Psychiatry. 2009 Sep 15;66(6):533-9. doi: 10.1016/j.biopsych.2009.05.006. Epub 2009 Jun 25. Biol Psychiatry. 2009. PMID: 19559402 Free article.

7

Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.

Stone JM. Stone JM. Curr Pharm Des. 2009;15(22):2594-602. doi: 10.2174/138161209788957438. Curr Pharm Des. 2009. PMID: 19689330 Review.

8

Abnormal thalamic glutamate and liability to psychosis: state or trait marker?

Stone JM, Fusar-Poli P. Stone JM, et al. Schizophr Res. 2009 Nov;115(1):94-5. doi: 10.1016/j.schres.2009.08.004. Epub 2009 Sep 5. Schizophr Res. 2009. PMID: 19734014 No abstract available.

9

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.

Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O' Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK. Bhattacharyya S, et al. Neuropsychopharmacology. 2010 Feb;35(3):764-74. doi: 10.1038/npp.2009.184. Epub 2009 Nov 18. Neuropsychopharmacology. 2010. PMID: 19924114 Free PMC article. Clinical Trial.

10

Review: The biological basis of antipsychotic response in schizophrenia.

Stone JM, Raffin M, Morrison P, McGuire PK. Stone JM, et al. J Psychopharmacol. 2010 Jul;24(7):953-64. doi: 10.1177/0269881109106959. Epub 2009 Nov 25. J Psychopharmacol. 2010. PMID: 19939865 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,306 results

Search Page